伊伐布雷定联合氨氯地平治疗慢性稳定性心绞痛的疗效观察

目的探究盐酸伊伐布雷定片联合苯磺酸氨氯地平片治疗慢性稳定性心绞痛的临床效果。方法选取2015年1月—2016年12月天津医科大学总医院滨海医院心内科收治的慢性稳定性心绞痛患者80例作为研究对象,将所有患者随机分为对照组和治疗组,每组各40例。对照组口服苯磺酸氨氯地平片,1片/次,1次/d。治疗组在对照组的基础上口服伊伐布雷定片,1片/次,2次/d。两组患者均连续治疗3个月。观察两组的临床疗效,比较两组的平板运动试验、西雅图心绞痛量表积分和心绞痛发作频率、心绞痛持续时间。结果治疗后,对照组和治疗组的总有效率分别为77.50%、95.00%,两组比较差异有统计学意义(P0.05)。治疗后,两组最高收缩压(SBP_(max))和最大心率(HR_(max))均明显升高,而ST/HR指数均明显降低(P0.05),同组治疗前后比较差异有统计学意义(P0.05);且治疗组这些观察指标的改善程度明显优于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,两组疾病认识程度、治疗满意程度、躯体活动受限程度、心绞痛稳定状态积分均明显升高,同组治疗前后比较差异有统计学意义(P0.05);且治疗组这些观察指标明显高于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,两组心绞痛发作频率和持续时间均显著降低,同组治疗前后比较差异有统计学意义(P0.05);且治疗组这些观察指标明显低于对照组,两组比较差异具有统计学意义(P0.05)。结论盐酸伊伐布雷定片联合苯磺酸氨氯地平片治疗慢性稳定性心绞痛具有较好的临床疗效,可改善临床症状,提高生活质量,安全性较高,具有一定的临床推广应用价值。

Clinical observation of ivabradine combined with amlodipine in treatment of chronic stable angina pectoris

Objective To investigate the clinical efficacy of Ivabradine Hydrochloride Tablets combined with Amlodiping Besylate Tablets in treatment of chronic stable angina pectoris. Methods Patients (80 cases) with chronic stable angina pectoris in Binhai Hospital of General Hospital Affiliated to Tianjin Medical University from January 2015 to December 2016 were randomly divided into control and treatment groups, and each group had 40 cases. Patients in the control group were po administered with Amlodiping Besylate Tablets, 1 tablet/time, once daily. Patients in the treatment group were po administered with Ivabradine Hydrochloride Tablets on the basis of the control group, 1 tablet/time, twice daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacies were evaluated, and treadmill exercise test, Seattle Angina Scale score, frequency and duration of angina pectoris in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 77.50% and 95.00%, respectively, and there was difference between two groups (P<0.05). After treatment, SBP_max and HR_max in two groups were significantly increased, but the ST/HR index in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, the scores of disease awareness, treatment satisfaction, physical activity restriction, and angina pectoris stability in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P<0.05). After treatment, the frequency and duration of angina pectoris in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion Ivabradine Hydrochloride Tablets combined with Amlodiping Besylate Tablets has clinical curative effect in treatment of chronic stable angina pectoris, can improve clinical symptoms, and enhance the quality of life, with good safety, which has a certain clinical application value.